

**Date: December 10, 2025**

**BSE Limited**

P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**

Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Scrip Code: 543904**

**Symbol: MANKIND**

Dear Sir/ Madam,

**Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations)**

---

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has received an Order on 10 December 2025 from Office of the Principal Commissioner, Central GST & Central Excise, Patna issued by Joint Commissioner (“Department”) under the applicable provisions of the GST Act. The Company will file necessary appeal with the appellate authority in this regard. There is no material impact on financials, operations or other activities of the Company.

The detailed disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed as **Annexure-I**.

This is for your information and records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

**Hitesh Kumar Jain**  
Company Secretary &  
Compliance Officer

## Annexure – I

Disclosure as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr. No.	Details of event that needs to be provided	Details
1	Name of the authority	Joint Commissioner, CGST & C. Excise, Patna (“Department”)
2	Nature and details of the action(s) taken, initiated or order(s) passed;	The Company has received an Order from the Bihar GST Authority under applicable provisions of the Central Goods and Services Tax Act, 2017, for 5 years spanning from the financial year 2018-19 to 2022-23 levying penalty of INR 15,31,70,825/-
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority;	December 10, 2025
4	Details of the violation(s)/contravention(s) committed or alleged to be committed;	Disallowance of ITC on account of reconciliation differences in the GST returns.
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible;	<p>Based on the assessment of facts and prevailing law, the Company is of the view that the above referred Order is not tenable in law. The Company has adequate factual and legal grounds to substantiate its position and does not expect any material impact on financials or operations of the Company due to the said order.</p> <p>The Company will take appropriate action(s) for the same including filing of an appeal if required.</p> <p>There is no material impact on the company's financials, operations, or other activities.</p>

**MANKIND PHARMA LIMITED**

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600  
CIN No. L74899DL1991 PLC044843 • E-mail : [contact@mankindpharma.com](mailto:contact@mankindpharma.com) • [www.mankindpharma.com](http://www.mankindpharma.com)